Print

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors

Clinicaltrials.gov identifier:
NCT05252390 (https://clinicaltrials.gov/show/NCT05252390)


Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

About the Study

NOTE: This study is no longer recruiting patients. 

 

This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only. 

 

 

 

This Study is Open To:

NOTE: This study is no longer recruiting patients. 

This Study is Not Open To:

NOTE: This study is no longer recruiting patients. 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.